Lamotrigine
(Apo-Lamotrigine, Lamictal ODT Green Titration Kit, Lamictal XR, Lamictin)
|
-
59 (32%) experienced major efficacy
-
70 (38%) experienced moderate efficacy
-
23 (12%) experienced slight efficacy
-
7 (4%) experienced no efficacy
-
|
-
19 (10%) experienced severe side effects
-
33 (18%) experienced moderate side effects
-
58 (31%) experienced mild side effects
-
76 (41%) experienced no side effects
|
186 |
|
|
-
43 (39%) experienced major efficacy
-
35 (32%) experienced moderate efficacy
-
19 (17%) experienced slight efficacy
-
5 (5%) experienced no efficacy
-
|
-
27 (25%) experienced severe side effects
-
38 (35%) experienced moderate side effects
-
31 (28%) experienced mild side effects
-
14 (13%) experienced no side effects
|
110 |
Quetiapine
(Cobalt-Quetiapine, Qusel, Ketipinor, Ratio-Quetiapine)
|
-
26 (28%) experienced major efficacy
-
34 (37%) experienced moderate efficacy
-
10 (11%) experienced slight efficacy
-
10 (11%) experienced no efficacy
-
|
-
28 (30%) experienced severe side effects
-
34 (37%) experienced moderate side effects
-
22 (24%) experienced mild side effects
-
8 (9%) experienced no side effects
|
92 |
Individual Therapy
(Meditation - Reflection, Mentalization Based Therapy, Dialectical Behavior Individual Therapy, Drug Treatment Centers)
|
-
16 (27%) experienced major efficacy
-
17 (29%) experienced moderate efficacy
-
11 (19%) experienced slight efficacy
-
9 (15%) experienced no efficacy
-
|
-
1 (2%) experienced severe side effects
-
5 (8%) experienced moderate side effects
-
10 (17%) experienced mild side effects
-
43 (73%) experienced no side effects
|
59 |
|
|
-
18 (38%) experienced major efficacy
-
14 (29%) experienced moderate efficacy
-
4 (8%) experienced slight efficacy
-
1 (2%) experienced no efficacy
-
|
-
21 (44%) experienced severe side effects
-
12 (25%) experienced moderate side effects
-
10 (21%) experienced mild side effects
-
5 (10%) experienced no side effects
|
48 |
|
|
-
18 (44%) experienced major efficacy
-
13 (32%) experienced moderate efficacy
-
5 (12%) experienced slight efficacy
-
0 (0%) experienced no efficacy
-
|
-
7 (17%) experienced severe side effects
-
9 (22%) experienced moderate side effects
-
8 (20%) experienced mild side effects
-
17 (41%) experienced no side effects
|
41 |
|
|
-
9 (24%) experienced major efficacy
-
10 (27%) experienced moderate efficacy
-
6 (16%) experienced slight efficacy
-
5 (14%) experienced no efficacy
-
|
-
9 (24%) experienced severe side effects
-
9 (24%) experienced moderate side effects
-
9 (24%) experienced mild side effects
-
10 (27%) experienced no side effects
|
37 |
Bupropion
(Voxra, Voxra, Budeprion SR, Zetron)
|
-
8 (27%) experienced major efficacy
-
11 (37%) experienced moderate efficacy
-
1 (3%) experienced slight efficacy
-
5 (17%) experienced no efficacy
-
|
-
4 (13%) experienced severe side effects
-
4 (13%) experienced moderate side effects
-
11 (37%) experienced mild side effects
-
11 (37%) experienced no side effects
|
30 |
Olanzapine
(Teva Olanzapine, Novo-Olanzapine, Zyprexa Zydis, Zyprexa)
|
-
3 (19%) experienced major efficacy
-
7 (44%) experienced moderate efficacy
-
1 (6%) experienced slight efficacy
-
3 (19%) experienced no efficacy
-
|
-
7 (44%) experienced severe side effects
-
3 (19%) experienced moderate side effects
-
6 (38%) experienced mild side effects
-
0 (0%) experienced no side effects
|
16 |
|
|
-
6 (38%) experienced major efficacy
-
4 (25%) experienced moderate efficacy
-
4 (25%) experienced slight efficacy
-
1 (6%) experienced no efficacy
-
|
-
2 (13%) experienced severe side effects
-
5 (31%) experienced moderate side effects
-
6 (38%) experienced mild side effects
-
3 (19%) experienced no side effects
|
16 |
|
|
-
7 (47%) experienced major efficacy
-
2 (13%) experienced moderate efficacy
-
3 (20%) experienced slight efficacy
-
2 (13%) experienced no efficacy
-
|
-
1 (7%) experienced severe side effects
-
4 (27%) experienced moderate side effects
-
6 (40%) experienced mild side effects
-
4 (27%) experienced no side effects
|
15 |
|
|
-
4 (27%) experienced major efficacy
-
5 (33%) experienced moderate efficacy
-
1 (7%) experienced slight efficacy
-
0 (0%) experienced no efficacy
-
|
-
3 (20%) experienced severe side effects
-
7 (47%) experienced moderate side effects
-
2 (13%) experienced mild side effects
-
3 (20%) experienced no side effects
|
15 |
|
|
-
2 (17%) experienced major efficacy
-
5 (42%) experienced moderate efficacy
-
4 (33%) experienced slight efficacy
-
0 (0%) experienced no efficacy
-
|
-
1 (8%) experienced severe side effects
-
6 (50%) experienced moderate side effects
-
2 (17%) experienced mild side effects
-
3 (25%) experienced no side effects
|
12 |
|
|
-
3 (25%) experienced major efficacy
-
2 (17%) experienced moderate efficacy
-
2 (17%) experienced slight efficacy
-
2 (17%) experienced no efficacy
-
|
-
5 (42%) experienced severe side effects
-
0 (0%) experienced moderate side effects
-
1 (8%) experienced mild side effects
-
6 (50%) experienced no side effects
|
12 |
|
|
-
2 (18%) experienced major efficacy
-
3 (27%) experienced moderate efficacy
-
2 (18%) experienced slight efficacy
-
2 (18%) experienced no efficacy
-
|
-
5 (45%) experienced severe side effects
-
2 (18%) experienced moderate side effects
-
1 (9%) experienced mild side effects
-
3 (27%) experienced no side effects
|
11 |